Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.pmn.2022.05.003 | DOI Listing |
Psychol Addict Behav
January 2025
Edna Bennett Pierce Prevention Research Center, College of Health and Human Development, Pennsylvania State University.
Objective: Transdermal alcohol concentration (TAC) sensors provide a multidimensional characterization of drinking events that self-reports cannot. These profiles may differ in their associated day-level alcohol-related consequences, but no research has tested this. We address this using multilevel latent profile analysis.
View Article and Find Full Text PDFIn August 2024, The U.S. Food and Drug Administration rejected Lykos Therapeutics, Inc.
View Article and Find Full Text PDFTurk Arch Pediatr
January 2025
Department of Forensic Medicine, İstanbul Health and Technology University Faculty of Medicine, İstanbul, Türkiye.
This review synthesizes current research on domestic violence and sexual assault, focusing on their short-term and long-term effects on family dynamics, particularly on the development and well-being of children and adolescents. The article employs a curated body of literature, including surveys, reviews, program evaluations, and international health reports, to elucidate the direct and collateral damage caused by such trauma within families. The review critically examines the intersecting consequences of abuse, including immediate psychological distress and long-term socio-economic and educational disruptions for affected youths.
View Article and Find Full Text PDFCureus
December 2024
Clinical Pathology Department, Unidade Local de Saúde do Nordeste, Unidade Hospitalar de Bragança, Bragança, PRT.
The Chilaiditi sign is the presence of a loop of bowel interposed between the liver and the diaphragm. In most cases, the Chilaiditi sign is diagnosed as a rare incidental radiological finding on chest X-rays or the abdomen of asymptomatic patients. When associated with symptoms, it is named Chilaiditi syndrome.
View Article and Find Full Text PDFToxicol Rep
June 2025
Department of Pharmacology, Theodor Bilharz Research Institute, Warrak El-Hadar, Imbaba, Giza 12411, Egypt.
Despite significant breakthroughs in frontline cancer research and chemotherapy for hepatocellular carcinoma (HCC), many of the suggested drugs have high toxic side effects and resistance, limiting their clinical utility. Exploring potential therapeutic targets or novel combinations with fewer side effects is therefore crucial in combating this dreadful disease. The current study aims to use a novel combination of ponatinib and gossypol against the HepG2 cell line.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!